ALX Oncology Holdings Key Executives
This section highlights ALX Oncology Holdings's key executives, including their titles and compensation details.
Find Contacts at ALX Oncology Holdings
(Showing 0 of )
ALX Oncology Holdings Earnings
This section highlights ALX Oncology Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
$0.55
Stock Price
$29.11M
Market Cap
80
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for ALX Oncology Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $1.18M |
| Cost of Revenue | $- | $836.00K | $1.47M | $736.00K | $1.07M |
| Gross Profit | $- | $-836.00K | $-1.47M | $-736.00K | $107.00K |
| Gross Profit Ratio | 0.00% | - | - | - | 9.05% |
| Research and Development Expenses | $116.37M | $141.79M | $98.40M | $60.17M | $28.96M |
| General and Administrative Expenses | $26.09M | $28.48M | $29.04M | $23.39M | $14.81M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $26.09M | $28.48M | $29.04M | $23.39M | $14.81M |
| Other Expenses | $- | $- | $-260.00K | $84.00K | $-404.00K |
| Operating Expenses | $142.47M | $170.28M | $127.44M | $83.56M | $43.77M |
| Cost and Expenses | $142.47M | $170.28M | $127.44M | $83.56M | $44.84M |
| Interest Income | $9.37M | $10.65M | $4.04M | $91 | $124.00K |
| Interest Expense | $1.73M | $1.56M | $- | $13.00K | $811.00K |
| Depreciation and Amortization | $872.00K | $836.00K | $1.47M | $736.00K | $202.00K |
| EBITDA | $-132.25M | $-158.40M | $-121.95M | $-83.47M | $-43.46M |
| EBITDA Ratio | - | - | - | - | -3676.90% |
| Operating Income | $-142.47M | $-170.28M | $-127.44M | $-83.56M | $-43.66M |
| Operating Income Ratio | - | - | - | - | -3693.99% |
| Total Other Income Expenses Net | $7.62M | $9.47M | $4.02M | $71.00K | $-1.84M |
| Income Before Tax | $-134.85M | $-160.81M | $-123.42M | $-83.48M | $-45.50M |
| Income Before Tax Ratio | - | - | - | - | -3849.32% |
| Income Tax Expense | $- | $- | $64.00K | $-21.00K | $241.00K |
| Net Income | $-134.85M | $-160.81M | $-123.48M | $-83.46M | $-45.74M |
| Net Income Ratio | - | - | - | - | -3869.71% |
| EPS | $-2.58 | $-3.74 | $-3.03 | $-2.07 | $-1.15 |
| EPS Diluted | $-2.58 | $-3.74 | $-3.03 | $-2.07 | $-1.15 |
| Weighted Average Shares Outstanding | 52.17M | 42.99M | 40.70M | 40.31M | 39.84M |
| Weighted Average Shares Outstanding Diluted | 52.17M | 42.99M | 40.70M | 40.31M | 39.84M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $2.48M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $527.00K | $655.00K |
| Cost of Revenue | $- | $- | $220.00K | $214.00K | $207.00K | $209.00K | $513.00K | $518.00K | $413.00K | $- | $280.00K | $376.00K | $259.00K | $262.00K | $152.00K | $5.00K | $1 | $- | $479.00K | $596.00K |
| Gross Profit | $- | $- | $-220.00K | $-214.00K | $2.27M | $-209.00K | $-513.00K | $-518.00K | $-413.00K | $- | $-280.00K | $-376.00K | $-259.00K | $-262.00K | $-152.00K | $-5.00K | $0 | $- | $48.00K | $59.00K |
| Gross Profit Ratio | - | 0.00% | - | - | 91.65% | - | - | - | - | - | - | - | - | - | - | - | 9.05% | 0.00% | 9.11% | 9.01% |
| Research and Development Expenses | $23.53M | $26.47M | $34.65M | $31.72M | $41.78M | $45.77M | $29.48M | $24.76M | $25.20M | $29.38M | $26.75M | $17.07M | $20.89M | $18.21M | $11.21M | $9.85M | $12.14M | $5.33M | $7.66M | $3.83M |
| General and Administrative Expenses | $7.08M | $6.10M | $6.87M | $6.04M | $6.24M | $7.51M | $7.29M | $7.44M | $7.02M | $7.30M | $7.04M | $7.67M | $7.58M | $6.36M | $5.09M | $4.36M | $5.68M | $4.48M | $3.17M | $1.47M |
| Selling and Marketing Expenses | $- | $- | $-220.00K | $-214.00K | $-207.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $7.08M | $6.10M | $6.65M | $5.83M | $6.03M | $7.51M | $7.29M | $7.44M | $7.02M | $7.30M | $7.04M | $7.67M | $7.58M | $6.36M | $5.09M | $4.36M | $5.68M | $4.48M | $3.17M | $1.47M |
| Other Expenses | $- | $- | $-8.00K | $-14.00K | $-29.00K | $-1.00K | $324.00K | $95.00K | $-233.00K | $-9.00K | $-7.00K | $-11.00K | $16.00K | $14.00K | $28.00K | $26.00K | $5.00K | $-111.00K | $-305.00K | $7.00K |
| Operating Expenses | $30.61M | $32.57M | $41.30M | $37.55M | $47.82M | $53.27M | $36.78M | $32.20M | $32.22M | $36.68M | $33.79M | $24.75M | $28.47M | $24.58M | $16.30M | $14.21M | $17.82M | $9.81M | $10.84M | $5.30M |
| Cost and Expenses | $30.61M | $32.57M | $41.52M | $37.76M | $48.02M | $53.27M | $36.78M | $32.20M | $32.22M | $36.68M | $33.79M | $24.75M | $28.47M | $24.58M | $16.30M | $14.21M | $17.82M | $9.81M | $11.31M | $5.90M |
| Interest Income | $1.88M | $2.30M | $2.56M | $2.62M | $3.00M | $2.68M | $2.67M | $2.31M | $1.81M | $1.37M | $876.00K | $225.00K | $- | $22.00K | $23.00K | $25.00K | $- | $- | $- | $- |
| Interest Expense | $427.00K | $446.00K | $429.00K | $427.00K | $415.00K | $391.00K | $372.00K | $387.00K | $- | $2.00K | $876.00K | $225.00K | $3.00K | $4.00K | $3.00K | $3.00K | $151.00K | $226.00K | $219.00K | $215.00K |
| Depreciation and Amortization | $214.00K | $224.00K | $220.00K | $214.00K | $207.00K | $209.00K | $513.00K | $518.00K | $413.00K | $95.00K | $280.00K | $376.00K | $259.00K | $262.00K | $152.00K | $5.00K | $5.00K | $5.00K | $79.00K | $113.00K |
| EBITDA | $-28.52M | $-30.04M | $-38.75M | $-34.94M | $-44.85M | $-50.39M | $-33.27M | $-29.28M | $-32.11M | $-34.92M | $-32.64M | $-24.16M | $-28.42M | $-24.56M | $-16.27M | $-14.20M | $-18.44M | $-9.91M | $-11.01M | $-5.12M |
| EBITDA Ratio | - | - | - | - | -1808.47% | - | - | - | - | - | - | - | - | - | - | - | -1559729272.42% | - | -2089.75% | -781.98% |
| Operating Income | $-30.61M | $-32.57M | $-41.52M | $-37.76M | $-48.02M | $-53.27M | $-36.78M | $-32.20M | $-32.22M | $-36.68M | $-33.79M | $-24.75M | $-28.47M | $-24.58M | $-16.30M | $-14.21M | $-17.82M | $-9.81M | $-10.79M | $-5.24M |
| Operating Income Ratio | - | - | - | - | -1936.41% | - | - | - | - | - | - | - | - | - | - | - | -1508037225.04% | - | -2046.87% | -800.31% |
| Total Other Income Expenses Net | $1.45M | $1.86M | $2.13M | $2.18M | $2.55M | $2.29M | $2.62M | $2.02M | $1.57M | $1.36M | $869.00K | $214.00K | $13.00K | $10.00K | $25.00K | $23.00K | $-767.00K | $-337.00K | $-524.00K | $-208.00K |
| Income Before Tax | $-29.16M | $-30.71M | $-39.40M | $-35.58M | $-45.47M | $-50.99M | $-34.16M | $-30.18M | $-30.64M | $-35.32M | $-32.92M | $-24.53M | $-28.46M | $-24.57M | $-16.27M | $-14.19M | $-18.59M | $-10.15M | $-11.31M | $-5.45M |
| Income Before Tax Ratio | - | - | - | - | -1833.55% | - | - | - | - | - | - | - | - | - | - | - | -1572927241.96% | - | -2146.30% | -832.06% |
| Income Tax Expense | $- | $- | $- | $170.72K | $1.15M | $-209.00K | $696.00K | $-1.63M | $64.00K | $-1.37M | $-869.00K | $-214.00K | $-21.00K | $18.00K | $31.00K | $29.00K | $182.00K | $35.00K | $20.00K | $4.00K |
| Net Income | $-29.16M | $-30.71M | $-39.40M | $-35.58M | $-45.47M | $-50.99M | $-34.16M | $-28.55M | $-30.71M | $-35.32M | $-32.05M | $-24.32M | $-28.44M | $-24.57M | $-16.27M | $-14.19M | $-18.77M | $-10.18M | $-11.33M | $-5.45M |
| Net Income Ratio | - | - | - | - | -1833.55% | - | - | - | - | - | - | - | - | - | - | - | -1588324873.10% | - | -2150.09% | -832.67% |
| EPS | $-0.55 | $-0.58 | $-0.76 | $-0.71 | $-0.93 | $-1.24 | $-0.84 | $-0.70 | $-0.75 | $-0.87 | $-0.79 | $-0.60 | $-0.70 | $-0.61 | $-0.40 | $-0.35 | $-0.50 | $-0.34 | $-0.33 | $-0.16 |
| EPS Diluted | $-0.55 | $-0.58 | $-0.76 | $-0.71 | $-0.93 | $-1.24 | $-0.84 | $-0.70 | $-0.75 | $-0.87 | $-0.79 | $-0.60 | $-0.70 | $-0.61 | $-0.40 | $-0.35 | $-0.50 | $-0.34 | $-0.33 | $-0.16 |
| Weighted Average Shares Outstanding | 52.80M | 52.69M | 51.83M | 50.12M | 49.00M | 41.15M | 40.88M | 40.86M | 40.76M | 40.75M | 40.69M | 40.62M | 40.53M | 40.40M | 40.25M | 40.06M | 37.64M | 29.66M | 34.71M | 34.71M |
| Weighted Average Shares Outstanding Diluted | 52.80M | 52.69M | 51.83M | 50.12M | 49.00M | 41.15M | 40.88M | 40.86M | 40.76M | 40.75M | 40.69M | 40.62M | 40.53M | 40.40M | 40.25M | 40.06M | 37.64M | 29.66M | 34.71M | 34.71M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $17.57M | $22.41M | $282.91M | $363.67M | $434.22M |
| Short Term Investments | $110.19M | $160.33M | $217.38M | $- | $- |
| Cash and Short Term Investments | $127.76M | $182.74M | $282.91M | $363.67M | $434.22M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $-17.70M | $- | $- |
| Other Current Assets | $6.59M | $5.92M | $4.76M | $6.70M | $3.55M |
| Total Current Assets | $134.35M | $188.66M | $270.97M | $367.02M | $434.22M |
| Property Plant Equipment Net | $2.90M | $10.84M | $9.81M | $3.47M | $52.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $3.52M | $35.41M | $16.70M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.99M | $7.64M | $9.01M | $9.69M | $1.78M |
| Total Non-Current Assets | $13.42M | $53.89M | $35.52M | $13.16M | $1.83M |
| Other Assets | $- | $- | $- | $- | $0 |
| Total Assets | $147.78M | $242.55M | $306.49M | $380.18M | $436.05M |
| Account Payables | $4.50M | $8.59M | $8.07M | $3.76M | $4.00K |
| Short Term Debt | $435.00K | $1.57M | $1.04M | $742.00K | $- |
| Tax Payables | $- | $- | $- | $- | $179.00K |
| Deferred Revenue | $- | $- | $- | $10.53M | $- |
| Other Current Liabilities | $13.57M | $25.84M | $19.21M | $10.79M | $6.02M |
| Total Current Liabilities | $18.50M | $36.00M | $28.32M | $15.29M | $6.20M |
| Long Term Debt | $- | $15.62M | $9.39M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $15.66M | $1.22M | $5.31M | $1.84M | $5.00K |
| Total Non-Current Liabilities | $15.66M | $16.84M | $14.70M | $1.84M | $5.00K |
| Other Liabilities | $- | $- | $- | $- | $429.85M |
| Total Liabilities | $34.16M | $52.84M | $43.02M | $17.13M | $436.05M |
| Preferred Stock | $- | $- | $- | $- | $436.05M |
| Common Stock | $53.00K | $50.00K | $41.00K | $41.00K | $40.00K |
| Retained Earnings | $-621.12M | $-486.27M | $-325.47M | $-201.99M | $-118.52M |
| Accumulated Other Comprehensive Income Loss | $275.00K | $256.00K | $-845.00K | $-0 | $-554.62M |
| Other Total Stockholders Equity | $734.41M | $675.68M | $589.74M | $564.99M | $548.33M |
| Total Stockholders Equity | $113.62M | $189.71M | $-325.47M | $-201.99M | $-118.52M |
| Total Equity | $113.62M | $189.71M | $-325.47M | $-201.99M | $-118.52M |
| Total Liabilities and Stockholders Equity | $147.78M | $242.55M | $-282.44M | $-184.85M | $436.05M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $147.78M | $242.55M | $-282.44M | $-184.85M | $436.05M |
| Total Investments | $113.71M | $195.74M | $234.08M | $- | $- |
| Total Debt | $435.00K | $17.20M | $10.43M | $742.00K | $- |
| Net Debt | $-17.13M | $-5.21M | $-272.48M | $-362.93M | $-434.22M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $17.57M | $16.10M | $15.53M | $14.04M | $22.41M | $19.58M | $38.04M | $63.19M | $282.91M | $49.05M | $66.38M | $159.09M | $363.67M | $385.15M | $409.96M | $429.86M | $434.22M | $259.48M | $98.10M | $105.03M |
| Short Term Investments | $110.19M | $132.47M | $141.19M | $143.40M | $160.33M | $170.43M | $174.80M | $164.75M | $217.38M | $235.85M | $246.99M | $157.51M | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $127.76M | $148.57M | $156.72M | $157.44M | $182.74M | $196.44M | $212.84M | $227.94M | $282.91M | $284.91M | $313.37M | $316.60M | $363.67M | $385.15M | $409.96M | $429.86M | $434.22M | $259.48M | $98.10M | $105.03M |
| Net Receivables | $- | $1.18M | $6.24M | $1.10M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $527.00K | $527.00K | $1.19M |
| Inventory | $- | $25.00K | $- | $- | $- | $-7.04M | $-500.00K | $-800.00K | $-17.70M | $- | $-900.00K | $-600.00K | $- | $- | $- | $- | $- | $- | $641.00K | $- |
| Other Current Assets | $6.59M | $6.11M | $5.75M | $10.43M | $5.92M | $9.06M | $6.72M | $4.59M | $4.76M | $11.80M | $6.96M | $9.86M | $6.70M | $7.63M | $4.63M | $4.94M | $3.55M | $2.39M | $2.03M | $1.19M |
| Total Current Assets | $134.35M | $155.90M | $168.71M | $167.86M | $188.66M | $199.07M | $219.56M | $232.54M | $270.97M | $290.81M | $316.85M | $321.52M | $367.02M | $388.96M | $412.28M | $432.33M | $434.22M | $262.40M | $100.66M | $107.41M |
| Property Plant Equipment Net | $9.63M | $10.31M | $10.70M | $10.24M | $10.84M | $9.81M | $9.07M | $9.55M | $9.81M | $8.64M | $8.23M | $6.97M | $3.47M | $562.00K | $167.00K | $47.00K | $52.00K | $45.00K | $37.00K | $757.00K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $3.52M | $14.04M | $29.54M | $27.11M | $35.48M | $6.43M | $11.65M | $28.22M | $16.70M | $8.22M | $10.86M | $25.11M | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $267.00K | $5.47M | $5.66M | $7.43M | $7.58M | $4.79M | $5.66M | $7.83M | $9.01M | $10.03M | $10.08M | $10.07M | $9.69M | $10.20M | $8.85M | $536.00K | $1.78M | $- | $2.41M | $229.00K |
| Total Non-Current Assets | $13.42M | $29.82M | $45.91M | $44.79M | $53.89M | $21.04M | $26.37M | $45.60M | $35.52M | $26.88M | $29.17M | $42.15M | $13.16M | $10.77M | $9.01M | $583.00K | $1.83M | $45.00K | $2.45M | $986.00K |
| Other Assets | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $147.78M | $185.72M | $214.62M | $212.65M | $242.55M | $220.11M | $245.93M | $278.14M | $306.49M | $317.69M | $346.02M | $363.68M | $380.18M | $399.73M | $421.29M | $432.91M | $436.05M | $262.45M | $103.11M | $108.40M |
| Account Payables | $4.50M | $7.89M | $8.15M | $6.23M | $8.59M | $13.00M | $4.12M | $9.83M | $8.07M | $5.88M | $8.68M | $5.13M | $3.76M | $3.68M | $5.81M | $7.35M | $4.00K | $1.42M | $1.86M | $1.99M |
| Short Term Debt | $435.00K | $- | $1.74M | $1.79M | $1.57M | $- | $- | $956.00K | $1.04M | $1.12M | $1.07M | $1.02M | $742.00K | $703.00K | $539.00K | $235.00K | $- | $2.57M | $1.71M | $857.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $179.00K | $179.00K | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $-823.00K | $-800.00K | $- | $- | $17.35M | $- | $- | $10.53M | $8.00M | $7.43M | $6.44M | $- | $2.96M | $3.84M | $797.00K |
| Other Current Liabilities | $13.57M | $24.45M | $28.56M | $24.21M | $25.84M | $22.14M | $13.46M | $11.11M | $19.21M | $18.25M | $14.20M | $9.15M | $10.79M | $8.10M | $7.63M | $6.37M | $6.02M | $3.21M | $4.14M | $1.15M |
| Total Current Liabilities | $18.50M | $32.34M | $38.45M | $32.23M | $36.00M | $35.14M | $17.57M | $21.89M | $28.32M | $25.24M | $23.95M | $15.31M | $15.29M | $12.49M | $13.98M | $14.13M | $6.20M | $7.20M | $7.72M | $3.99M |
| Long Term Debt | $9.47M | $9.84M | $15.73M | $15.06M | $15.62M | $9.57M | $9.51M | $9.45M | $9.39M | $5.48M | $- | $- | $- | $- | $- | $- | $- | $3.19M | $3.93M | $4.67M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $108.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $6.19M | $6.73M | $1.12M | $1.17M | $1.22M | $6.64M | $6.16M | $6.41M | $5.31M | $- | $5.75M | $4.77M | $1.84M | $- | $2.30M | $297.00K | $5.00K | $47.00K | $820.00K | $620.00K |
| Total Non-Current Liabilities | $15.66M | $16.57M | $16.85M | $16.23M | $16.84M | $16.21M | $15.67M | $15.86M | $14.70M | $5.48M | $5.75M | $4.77M | $1.84M | $2.07M | $2.30M | $297.00K | $5.00K | $3.24M | $4.75M | $5.29M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $429.85M | $- | $- | $- |
| Total Liabilities | $34.16M | $48.91M | $55.30M | $48.45M | $52.84M | $51.35M | $33.24M | $37.75M | $43.02M | $30.73M | $29.70M | $20.08M | $17.13M | $14.56M | $16.27M | $14.43M | $436.05M | $10.43M | $12.47M | $9.28M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $0 | $- | $- | $262.45M | $175.04M | $175.04M |
| Common Stock | $53.00K | $53.00K | $52.00K | $50.00K | $50.00K | $41.00K | $41.00K | $41.00K | $41.00K | $41.00K | $41.00K | $41.00K | $41.00K | $40.00K | $40.00K | $40.00K | $40.00K | $37.00K | $3.00K | $3.00K |
| Retained Earnings | $-621.12M | $-591.96M | $-561.25M | $-521.85M | $-486.27M | $-440.80M | $-389.81M | $-355.65M | $-325.47M | $-294.76M | $-259.44M | $-226.52M | $-201.99M | $-173.55M | $-148.98M | $-132.71M | $-118.52M | $-99.75M | $-89.57M | $-78.24M |
| Accumulated Other Comprehensive Income Loss | $275.00K | $563.00K | $-73.00K | $28.00K | $256.00K | $-226.00K | $-312.00K | $-88.00K | $-845.00K | $-1.50M | $-1.26M | $-606.00K | $-0 | $0 | $-0 | $-30.00K | $0 | $-97.00K | $-92.00K | $-1.56M |
| Other Total Stockholders Equity | $734.41M | $728.15M | $720.59M | $685.97M | $675.68M | $609.74M | $602.77M | $596.09M | $589.74M | $583.18M | $576.97M | $570.68M | $564.99M | $558.68M | $553.96M | $551.15M | $548.33M | $351.73M | $5.17M | $3.87M |
| Total Stockholders Equity | $113.62M | $136.81M | $159.32M | $164.19M | $189.71M | $-440.80M | $212.69M | $240.39M | $-325.47M | $286.96M | $316.32M | $343.60M | $-201.99M | $385.17M | $405.01M | $418.48M | $429.85M | $252.02M | $90.64M | $99.12M |
| Total Equity | $113.62M | $136.81M | $159.32M | $164.19M | $189.71M | $-440.80M | $212.69M | $240.39M | $-325.47M | $286.96M | $316.32M | $343.60M | $-201.99M | $385.17M | $405.01M | $418.48M | $429.85M | $252.02M | $90.64M | $99.12M |
| Total Liabilities and Stockholders Equity | $147.78M | $185.72M | $214.62M | $212.65M | $242.55M | $-389.44M | $245.93M | $278.14M | $-282.44M | $317.69M | $346.02M | $363.68M | $-184.85M | $399.73M | $421.29M | $432.91M | $436.05M | $262.45M | $103.11M | $108.40M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $147.78M | $185.72M | $214.62M | $212.65M | $242.55M | $-389.44M | $245.93M | $278.14M | $-282.44M | $317.69M | $346.02M | $363.68M | $-184.85M | $399.73M | $421.29M | $432.91M | $436.05M | $262.45M | $103.11M | $108.40M |
| Total Investments | $113.71M | $146.51M | $170.73M | $170.51M | $195.81M | $176.86M | $186.44M | $192.97M | $234.08M | $244.07M | $257.85M | $182.62M | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $9.90M | $9.84M | $17.47M | $16.84M | $17.20M | $9.57M | $9.51M | $10.41M | $10.43M | $6.60M | $1.07M | $1.02M | $742.00K | $703.00K | $539.00K | $235.00K | $- | $5.76M | $5.64M | $5.53M |
| Net Debt | $-7.66M | $-6.27M | $1.94M | $2.80M | $-5.21M | $-10.01M | $-28.53M | $-52.79M | $-272.48M | $-42.45M | $-65.30M | $-158.06M | $-362.93M | $-384.45M | $-409.43M | $-429.62M | $-434.22M | $-253.72M | $-92.46M | $-99.51M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-134.85M | $-160.81M | $-123.48M | $-83.46M | $-45.74M |
| Depreciation and Amortization | $872.00K | $836.00K | $342.00K | $51.00K | $202.00K |
| Deferred Income Tax | $- | $- | $- | $- | $1.27M |
| Stock Based Compensation | $27.09M | $26.27M | $23.84M | $13.91M | $5.44M |
| Change in Working Capital | $-12.43M | $8.30M | $9.85M | $-4.03M | $247.00K |
| Accounts Receivables | $- | $- | $- | $- | $536.00K |
| Inventory | $- | $- | $- | $- | $-536.00K |
| Accounts Payables | $-4.02M | $458.00K | $4.51M | $3.29M | $-3.74M |
| Other Working Capital | $-8.41M | $7.84M | $5.34M | $-7.32M | $3.99M |
| Other Non Cash Items | $-2.60M | $-4.96M | $228.00K | $5.42M | $295.00K |
| Net Cash Provided by Operating Activities | $-121.91M | $-130.36M | $-89.22M | $-68.10M | $-38.29M |
| Investments in Property Plant and Equipment | $-447.00K | $-1.27M | $-1.43M | $-4.92M | $-31.00K |
| Acquisitions Net | $- | $- | $233.99K | $- | $641.00K |
| Purchases of Investments | $-107.41M | $-246.63M | $-376.79M | $- | $- |
| Sales Maturities of Investments | $194.11M | $292.56M | $142.80M | $- | $- |
| Other Investing Activities | $- | $- | $-233.99K | $-4.26M | $641.00K |
| Net Cash Used for Investing Activities | $86.26M | $44.66M | $-235.42M | $-4.92M | $610.00K |
| Debt Repayment | $-827.00K | $-388.00K | $9.61M | $-281.00K | $-6.51M |
| Common Stock Issued | $- | $58.89M | $903.00K | $2.75M | $368.26M |
| Common Stock Repurchased | $351.00K | $- | $336.00K | $202.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $-3.00K |
| Other Financing Activities | $31.64M | $792.00K | $248.00K | $2.75M | $104.68M |
| Net Cash Used Provided by Financing Activities | $30.82M | $59.29M | $9.86M | $2.47M | $462.88M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-4.84M | $-26.42M | $-314.78M | $-70.55M | $425.20M |
| Cash at End of Period | $17.63M | $22.47M | $48.89M | $363.67M | $434.22M |
| Cash at Beginning of Period | $22.47M | $48.89M | $363.67M | $434.22M | $9.02M |
| Operating Cash Flow | $-121.91M | $-130.36M | $-89.22M | $-68.10M | $-38.29M |
| Capital Expenditure | $-447.00K | $-1.27M | $-1.43M | $-4.92M | $-31.00K |
| Free Cash Flow | $-122.36M | $-131.64M | $-90.65M | $-73.02M | $-38.32M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-29.16M | $-30.71M | $-39.40M | $-35.58M | $-45.47M | $-50.99M | $-34.16M | $-30.18M | $-30.71M | $-35.32M | $-32.92M | $-24.53M | $-28.44M | $-24.57M | $-16.27M | $-14.19M | $-18.77M | $-10.18M | $-11.33M | $-5.45M |
| Depreciation and Amortization | $214.00K | $224.00K | $220.00K | $214.00K | $207.00K | $209.00K | $207.00K | $213.00K | $105.00K | $95.00K | $84.00K | $58.00K | $34.00K | $6.00K | $6.00K | $5.00K | $5.00K | $5.00K | $79.00K | $113.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-11.62M | $-1.84M | $-1.65M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $621.00K | $242.00K | $308.00K | $100.00K |
| Stock Based Compensation | $5.86M | $6.95M | $7.25M | $7.03M | $6.72M | $6.96M | $6.24M | $6.35M | $6.29M | $6.21M | $5.84M | $5.50M | $5.69M | $4.19M | $2.24M | $1.80M | $1.74M | $689.00K | $2.85M | $151.00K |
| Change in Working Capital | $-8.76M | $-1.32M | $6.21M | $-8.56M | $331.00K | $14.13M | $-2.71M | $-3.45M | $3.97M | $-1.81M | $9.81M | $-2.12M | $266.00K | $-4.74M | $-6.74M | $7.19M | $2.71M | $-295.00K | $1.81M | $-3.98M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $536.00K | $- | $664 | $-655 |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.60M | $- | $- | $- |
| Accounts Payables | $-3.78M | $-194.00K | $1.88M | $-2.33M | $-4.48M | $8.89M | $-5.71M | $1.77M | $2.45M | $-3.06M | $3.56M | $1.55M | $-330.00K | $-2.18M | $-1.54M | $7.35M | $-1.42M | $-320.00K | $-242.00K | $-1.76M |
| Other Working Capital | $-4.98M | $-1.13M | $4.33M | $-6.23M | $4.82M | $5.24M | $3.00M | $-1.77M | $1.52M | $1.26K | $6.25M | $-3.68M | $596.00K | $-2.56M | $-5.19M | $-159.00K | $-9.00K | $25.00K | $2.06M | $-2.22M |
| Other Non Cash Items | $-195.00K | $-523.00K | $4.96M | $8.76M | $10.15M | $372.00K | $368.00K | $-748.00K | $-332.00K | $302.00K | $192.00K | $425.00K | $4.96M | $256.00K | $146.00K | $58.00K | $82.00K | $-8.00K | $113.00K | $108.00K |
| Net Cash Provided by Operating Activities | $-32.05M | $-25.38M | $-26.57M | $-37.92M | $-39.68M | $-31.16M | $-31.71M | $-27.82M | $-20.67M | $-30.88M | $-17.00M | $-20.67M | $-17.49M | $-24.86M | $-20.62M | $-5.13M | $-13.62M | $-9.55M | $-6.16M | $-8.96M |
| Investments in Property Plant and Equipment | $-60.00K | $-149.00K | $-90.00K | $-148.00K | $-148.00K | $1.30M | $-1.74M | $-690.00K | $-389.00K | $-192.00K | $-257.00K | $-589.00K | $-4.52M | $-398.00K | $- | $-7.00K | $-11.00K | $-10.00K | $- | $-10.00K |
| Acquisitions Net | $- | $- | $- | $- | $50.94K | $- | $-7.95K | $-42.98K | $-11.33K | $- | $75.88K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-4.44M | $-8.71M | $-62.96M | $-31.29M | $-75.01M | $-52.89M | $-46.53M | $-72.20M | $-60.97M | $-36.61M | $-95.88M | $-183.33M | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $37.69M | $34.55M | $63.96M | $57.91M | $58.49M | $64.40M | $54.48M | $115.19M | $72.30M | $50.50M | $20.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $26.62K | $-16.52K | $11.51K | $7.95K | $42.98K | $11.33K | $13.89K | $-75.88K | $-183.33K | $-4.26M | $- | $- | $- | $- | $641.00K | $- | $- |
| Net Cash Used for Investing Activities | $33.18M | $25.69M | $907.00K | $26.47M | $-16.67M | $12.81M | $6.21M | $42.30M | $10.94M | $13.70M | $-76.13M | $-183.92M | $-4.52M | $-398.00K | $- | $-7.00K | $-11.00K | $631.00K | $- | $-10.00K |
| Debt Repayment | $-76.00K | $-358.00K | $-218.00K | $-175.00K | $-63.00K | $-111.00K | $-107.00K | $-107.00K | $9.24M | $-141.00K | $-35.00K | $-105.00K | $-104.00K | $-104.00K | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-29.30M | $75.00K | $26.20M | $3.02M | $59.23M | $- | $450.00K | $- | $256.00K | $- | $457.00K | $185.00K | $-103.00K | $543.00K | $804.00K | $778.00K | $368.26M | $172.72M | $- | $- |
| Common Stock Repurchased | $- | $306.00K | $- | $- | $523.00K | $- | $- | $- | $336.00K | $- | $- | $- | $- | $- | $- | $- | $-179.28M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-3.00K | $- | $- | $- |
| Other Financing Activities | $29.71M | $534.00K | $1.17M | $237.00K | $59.23M | $- | $450.00K | $- | $- | $5.00K | $457.00K | $185.00K | $628.00K | $543.00K | $731.00K | $778.00K | $188.36M | $-2.43M | $-769.00K | $104.99M |
| Net Cash Used Provided by Financing Activities | $328.00K | $251.00K | $27.15M | $3.09M | $59.17M | $-111.00K | $343.00K | $-107.00K | $9.49M | $-136.00K | $422.00K | $80.00K | $524.00K | $439.00K | $731.00K | $778.00K | $188.36M | $170.30M | $-769.00K | $104.99M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-50.41M | $22.18M | $28.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.47M | $568.00K | $1.49M | $-8.37M | $2.82M | $-18.45M | $-25.16M | $14.37M | $-232.00K | $-17.32M | $-92.71M | $-204.51M | $-21.48M | $-24.82M | $-19.89M | $-4.36M | $174.74M | $161.38M | $-6.93M | $96.02M |
| Cash at End of Period | $17.63M | $16.17M | $15.53M | $14.04M | $22.41M | $19.65M | $38.10M | $63.26M | $48.89M | $49.12M | $66.44M | $159.15M | $363.67M | $385.15M | $409.96M | $429.86M | $434.22M | $259.48M | $98.10M | $105.03M |
| Cash at Beginning of Period | $16.17M | $15.60M | $14.04M | $22.41M | $19.58M | $38.10M | $63.26M | $48.89M | $49.12M | $66.44M | $159.15M | $363.67M | $385.15M | $409.96M | $429.86M | $434.22M | $259.48M | $98.10M | $105.03M | $9.02M |
| Operating Cash Flow | $-32.05M | $-25.38M | $-26.57M | $-37.92M | $-39.68M | $-31.16M | $-31.71M | $-27.82M | $-20.67M | $-30.88M | $-17.00M | $-20.67M | $-17.49M | $-24.86M | $-20.62M | $-5.13M | $-13.62M | $-9.55M | $-6.16M | $-8.96M |
| Capital Expenditure | $-60.00K | $-149.00K | $-90.00K | $-148.00K | $-148.00K | $1.30M | $-1.74M | $-690.00K | $-389.00K | $-192.00K | $-257.00K | $-589.00K | $-4.52M | $-398.00K | $- | $-7.00K | $-11.00K | $-10.00K | $- | $-10.00K |
| Free Cash Flow | $-32.11M | $-25.52M | $-26.66M | $-38.07M | $-39.83M | $-29.86M | $-33.45M | $-28.51M | $-21.06M | $-31.07M | $-17.25M | $-21.26M | $-22.01M | $-25.25M | $-20.62M | $-5.14M | $-13.63M | $-9.56M | $-6.16M | $-8.97M |
ALX Oncology Holdings Dividends
Explore ALX Oncology Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
ALX Oncology Holdings News
Read the latest news about ALX Oncology Holdings, including recent articles, headlines, and updates.
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place today at 6:00 a.m. PT/9:00 a.m.
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.
ALX Oncology to Host Virtual R&D Day on March 5, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m.
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, announced positive updated data from the ASPEN-06 Phase 2 clinical trial demonstrating that the company's investigational CD47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The updated results, which build upon previously announced topline results, will be shared today in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option to purchase a total of 600,000 shares of ALX Oncology's common stock to Harish Shantharam, the Company's Chief Financial Officer, in connection with the commencement of his employment. Mr. Shantharam's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to Mr. Shantharam to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the company will host a virtual event on Thursday, January 23, at 1:00 p.m. PT/4:00 p.m. ET to discuss updated data from the ASPEN-06 Phase 2 clinical trial evaluating the company's investigational CD47-blocker evorpacept in patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ALX Oncology Holdings (ALXO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%.
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced topline data from its Phase 2 ASPEN-06 clinical trial. The trial demonstrated clinically meaningful improvements in overall response rate and duration of response among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and trials. Financially, ALXO has a reasonable cash pool to fund operations for the near term, with a runway of 5-6 quarters.
Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for ALX Oncology Holdings (ALXO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology (“ASCO”) Annual Meeting being held in Chicago from May 31-June 4, 2024. These findings represent the first evorpacept combination data with an ADC from ASPEN-07's ongoing, open-label, single-arm, clinical trial of evorpacept in combination with PADCEV (enfortumab vedotin or “EV”) in patients with locally advanced or metastatic urothelial cancer (“la/m UC”). Evorpacept is a CD47 blocker with an inactivated Fc effector domain that is designed to minimize associated toxicity.
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows:
Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet
The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
ALX Oncology Appoints Allison Dillon as Chief Business Officer
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”).
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024.
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus R2 was well tolerated with a safety profile similar to historical R2 – The combination achieved promising initial activity with a best overall response rate (“ORR”) of 94% and a complete response rate (“CRR”) of 83% in patients with indolent R/R B-NHL (R2 historical CRR benchmark is 34%)
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ALXO.